Modern Retina Summer 2023

The investigators have developed a clinically robust HH-SECTR system, which has a modular aluminum probe design and micrometer-scale mechanical stability.

The severity and duration of gene therapy–associated uveitis correlated with increasing vector dose.

A single, consistent modality leads to better geographic atrophy tracking.

As a nonsteroid treatment, RG6179 could open new methods for controlling inflammation with fewer adverse effects.

In-person and virtual trainings, coupled with the support of local product representatives, are the best ways to ensure retina specialists are set up for success.

How AI tools can drive early detection of diabetic eye conditions.

Real-world patients often fail to achieve and retain the visual acuity results observed in clinical trials for anti–VEGF-A therapy. Broader therapeutic inhibition of additional angiogenic factors VEGF-C and VEGF-D could change that.

Clinical benefit of complement inhibition has been demonstrated in clinical trials, but there are possible consequences to consider.

New treatment options enhance patient visual outcomes and reduce treatment burdens.